Cromos Pharma, where the patients are

Articles Published in 2007

CenterWatch Monthly November 2007 Issue

Friday, November 16, 2007 12:59 PM

Changes in Asia-Pacific Regulations Position Region for More Growth

More... »

CRF Health eCOA webinar series

Recent Industry Personnel News

Tuesday, November 13, 2007 06:55 PM

Contract Research

More... »

Top Stories for the Week of Nov. 5th 2007

Friday, November 9, 2007 05:00 PM

Top News

More... »

Drug for Excessive Sleepiness Shows Promise in Phase II Study

Thursday, November 8, 2007 10:23 AM

Vanda Pharmaceuticals reported positive results from a phase II trial of VSF-173, an orally administered stimulant, for the treatment of excessive sleepiness. This randomized, double-blind, placebo-controlled trial enrolled  fifty-five subjects who received three doses of VSF-173 administered at 50 mg, 100 mg and 200 mg and placebo administered at 25 mg, 50 mg and 100 mg at the usual bedtime and at four hours after the first dose.

More... »

Michael J. Fox Foundation Gets It and Gets It Done

Wednesday, November 7, 2007 11:09 AM

The Michael J. Fox Foundation (MJFF) for Parkinson's Research gets it. They have figured out just how many bottlenecks there are for getting good research out of academia and to the patient. And Michael J. Fox is willing to put its money where it is needed to move along the drug development process.

More... »

Parexel Reports 26% First Quarter Revenue Increase

Monday, November 5, 2007 04:17 PM

Boston, Mass.-based Parexel International reported service revenue increased 26.1% to $208.1 million for its first quarter of 2008 compared with $165.1 million during the same period of last year. The CRO ended the quarter with operating income of $16.5 million and margins of 7.9%. That compares with $11.3 million for the same period last year and a 6.9% margin. Net income for the quarter was $13.9 million compared with net income of $7 million.

More... »

Top Stories for the Week of Oct. 29th 2007

Friday, November 2, 2007 03:08 PM

Top News

More... »

Finally Out with the Old at PharmaNet?

Friday, November 2, 2007 12:10 PM

Some equity analysts remained on edge about PharmaNet Development Group’s recent personnel changes during its third quarter conference call on Nov. 1. But should they be?

More... »

NEJM Takes Shots at CROs

Wednesday, October 31, 2007 09:22 AM

A recent New England Journal of Medicine (NEJM) Perspective piece criticized the clinical trials industry for its reliance on contract research organizations (CROs). The piece describes the rapid growth in the CRO industry, questions the quality of research data it generates and cites various clinical trials that have shed some negative light on CRO-run studies.

More... »

Centocor Psoriasis Drug Shows Impressive Results

Monday, October 29, 2007 12:44 PM

Johnson & Johnson’s Centocor reported positive results from a phase III trial of CNTO1275 (ustekinumab) for the treatment of psoriasis. CNTO1275 is a monoclonal antibody (mAb) against the p40 subunit of interleukin 12 (IL-12) and IL-23. This randomized, double-blind, placebo-controlled study, dubbed PHOENIX 2, enrolled 1,230 subjects with chronic psoriasis.

More... »

CenterWatch Data Library



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs